<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2510200241
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MALAUST
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ATOVAQUONE,PROGUANIL HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250,100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        44.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Glenmark Pharmaceuticals Limited - Baddi" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Glenmark Pharmaceuticals Limited - Baddi
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glenmark Pharmaceuticals Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        P01BB51
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Malaust 250 mg/100 mg Film-coated tablets belong to a group of medicines called antimalarials. It contains two active ingredients, atovaquone and proguanil hydrochloride. Malaust 250 mg/100 mg Film-coated tablets have two uses:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to prevent malaria in adults and children who weigh more than 40 kg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat malaria in adults and children who weigh more than 11 kg</p><p>Malaria is spread by the bite of an infected mosquito, which passes the malaria parasite (Plasmodium falciparum) into the bloodstream. Malaust 250 mg/100 mg Film-coated tablets prevent malaria by killing this parasite. For people who are already infected with malaria, Malaust 250 mg/100 mg Film- coated tablets also kills these parasites.</p><p>&nbsp;</p><p><strong>Protect yourself from catching malaria </strong></p><p>People of any age can get malaria. It is a serious disease, but is preventable. As well as taking Malaust 250 mg/100 mg Film-coated tablets, it is very important that you also take steps to avoid being bitten by mosquitoes.<strong> </strong>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Use insect areas of the skin. </strong><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Wear light colored clothing that covers most of the body, especially after sunset as this is the time when mosquitoes are most active. </strong><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Sleep in a screened room or under a mosquito net impregnated with insecticide. </strong><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Close windows and doors at sunset, if they are not screened. </strong><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Consider using an insecticide (mats, spray, plug-ins) to clear a room of insects or to deter mosquitoes from entering the room</strong>. &nbsp;</p><p>&nbsp;</p><p><strong>If you need further advice</strong>, talk to your doctor or pharmacist</p><p><strong>It is still possible to get malaria after taking the necessary precautions</strong>. &nbsp;Some types of malaria infection take a long time to cause symptoms, so the illness may not start until several days, weeks or even months after returning from abroad.</p><p><strong>See a doctor immediately if you get symptoms</strong> such as high temperature, headache, shivering and tiredness &nbsp;after returning home. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Malaust</strong> 250 mg / 100 mg Film - coated tablets:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to Atovaquone and / or proguanil hydrochloride or any of the ingredients of this medicine (listed in section 6) &nbsp;. &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for preventing malaria, if you have severe kidney disease. &nbsp;</p><p><strong>Warnings and precautions </strong></p><p><strong>When preventing malaria: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are sick (vomit) within 1 hour of taking your Malaust 250 mg / 100 mg Film - coated tablet, take another dose straight away</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is important to take the full course of Malaust 250 mg / 100 &nbsp;mg Film - coated tablets. &nbsp;If you have to take extra tablets due to sickness, you may need another prescription. &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have been vomiting, it is especially important to use extra protecton, such as repellents and bed nets. &nbsp;Malaust 250 mg / 100 mg Film - coated tablets may not be as effective, as the amount absorbed will be reduced. &nbsp;</p><p>&nbsp;</p><p><strong>When treating malaria: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have vomiting and diarrhoea tell your doctor, you will need regular blood tests. &nbsp;Malaust 250 mg / 100 mg Film - coated tablets will not be as effective, as the amount absorbed will be reduced. &nbsp;The tests will check whether the malaria parasite is being cleared from your blood. &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe kidney disease, your doctor may want to prescribe a different medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get a certain type of infection whilst being treated with Malaust 250 mg / 100 mg Film coated tablets, your doctor may prescribe another type of medicine instead of Malaust250 mg Film - coated tablets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the malaria is treated but then comes back repeatedly or if certain type of parasite, your doctor may prescribe another medicine to be taken as well as Malaust 250 mg / 100 mg Film - coated tablets</p><p>&nbsp;</p><p><strong>Other medicines and Malaust 250 mg </strong><strong>&nbsp;</strong><strong>/ 100 mg film - coated tablets </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, Some medicines can affect the way Malaust 250 mg / 100 mg Film - coated tablets works, or Malaust 250 mg / &nbsp;100 mg Film - coated tablets themselves can strengthen or weaken the effectiveness of other medicines taken at the same time. &nbsp;These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metoclopramide, used to treat nausea and vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the antibiotics tetracycline, rifampicin and rifabutin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; efavirenz or certain highly active protease - inhibitors used to treat HIV</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indinavir, used to treat HIV</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin and other medicines that stop blood clotting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; etoposide used to treat cancer. &nbsp;</p><p>&nbsp;</p><p>Tell your doctor if you are taking any of these. &nbsp;Your doctor may decide that Malaust 250 mg / 100 mg Film - coated tablets aren&#39;t suitable for you, or that you need extra check ups while you&#39;re taking it. &nbsp;REMEMBER to tell your doctor if you start taking any other medicines while you&#39;re taking Malaust 250 mg / 100 mg Film - coated tablets. &nbsp;</p><p>&nbsp;</p><p><strong>Malaust with food and drink </strong></p><p>Take Malaust 250 mg / 100 mg Film - coated tablets with food or a milky wrink, where possible. &nbsp;This will increase the amount of Malaust 250 mg / 100 mg Film - coated tablets your body can absorb, and make your treatment more effective. &nbsp;</p><p>The tablets should preferably not be crushed. &nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy and breast - feeding </strong></p><p>If you are pregnant or if you have the intention to get pregnant, do not take Malaust 250 mg / 100 mg film - coated tablets unless your doctor recommends it. &nbsp;</p><p>Ask your doctor or pharmacist for advice before taking Malaust 250 mg / 100 mg Film - coated tablets. &nbsp;Do not breast feed while taking Malaust 250 mg / 100 mg Film - coated tablets, as the ingredients of Malaust 250 mg / 100 mg Film - coated tablets may pass into breast milk and may harm your baby. &nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>If you feel dizzy, do not drive. &nbsp;Malaust 250 mg / 100 mg Film - coated tablets make some people feel dizzy. &nbsp;If this happens to you, do not drive, use machines or take part in activities where you may put yourself or others at risk. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Malaust 250 mg coated tablets exactly as your doctor has told you. &nbsp;Check with your doctor or pharmacist if you are not sure. &nbsp;</p><p>Take Malaust 250 mg / 100 mg Film - coated tablets with food or a milky drink, where possible. &nbsp;It is best to take Malaust 250 mg / 100 mg Film - coated tablets at the same time each day. &nbsp;</p><p><strong>For preventing malaria </strong></p><p>The usual dose for adults and adolescents weighing more than 40 kg is 1 tablet once a day, taken as below. &nbsp;</p><p><strong>For children, talk to your doctor. </strong></p><p>Malaust 250 mg / 100 mg Film - coated tablets is not recommended for preventing malaria in children, or in adults or adolescents who weigh less than 40 kg. &nbsp;</p><p>There may be a different type of Malaust 250 mg / 100 mg film - coated tablets available for children in your country.</p><p><strong>To prevent malaria in adults: </strong></p><p>start taking Malaust 250 mg / 100 mg Film - coated tablets 1 to 2 days before traveling to an area &nbsp;which has malaria</p><p>continue taking it every day during your stay and then continue taking it for another 7 days after your return to a malaria - free area. &nbsp;Take the full course of Malaust 250 mg / 100 mg Film - coated tablets for maximum protection. &nbsp;Stopping early puts you at risk of getting malaria, as it takes 7 days to ensure that any parasites that may be in your blood following a bite from an infected mosquito are killed. &nbsp;</p><p>&nbsp;</p><p><strong>For treating malaria: </strong></p><p>The usual dose for adults is 4 tablets once a day for 3 days. &nbsp;</p><p>For children weighing 11 kg or more:</p><p>&ge; 11 to &le;20 kg - 1 tablet once a day for 3 days</p><p>&ge;21 to &le;30 kg - 2 tablets once a day for 3 days</p><p>&ge;31 to &le;240 kg - 3 tablets once a day for 3 days</p><p>Over 40 &nbsp;kg - dose for adults. &nbsp;</p><p>&nbsp;</p><p>Malaust 250 mg / 100 mg Film - coated tablets is not recommended for treating malaria in children who weigh less than 11 kg. &nbsp;</p><p>For children who weigh less than 11 kg talk to your doctor. &nbsp;There may be a different type of Malaust 250 mg / 100 mg Film - coated tablet available in your country</p><p><strong>If you take more Malaust than you should </strong></p><p>Contact a doctor or pharmacist for advice. &nbsp;If possible, show them the Malaust 250 mg / 100 mg Film coated tablets pack</p><p><strong>If you forget to take Malaust </strong></p><p>It is very important that you take the full course of Malaust 250 mg / 100 mg Film - coated tablets. &nbsp;If you forget to take a dose, don&#39;t worry. &nbsp;Just take your next dose as soon as you remember. &nbsp;Then continue your treatment as before. &nbsp;Don&#39;t take a double dose to make up for a missed dose. &nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Don&#39;t stop taking Atovaquone / Proguanil Hydrochloride without advice </strong></p><p><strong>Keep taking Atovaquone / Proguanil Hydrochloride for 7 days after you return to a malaria - free area</strong>. &nbsp;Take the full course of Atovaquone / Proguanil Hydrochloride for maximum protection. &nbsp;Stopping early puts you at risk of getting malaria, as it takes 7 days to ensure that any parasites that may be in your blood following a bite from an infected mosquito are killed. &nbsp;</p><p>&nbsp;</p><p>Please talk to your doctor or pharmacist if you need any advice. &nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine although not everybody them. &nbsp;Look out for the following severe reactions. &nbsp;They have occurred in a small number of people, but their exact frequency is unknown. &nbsp;</p><p>Severe allergic reactions - signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash and itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden wheezing, tightness of the chest or throat, or difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen eyelids, face, lips, tongue or other part of the body. &nbsp;</p><p>&nbsp;</p><p><strong>Contact a doctor immediately if you get any of these symptoms. </strong><strong>&nbsp;</strong><strong>Stop taking Malaust 250 mg / 100 mg Film - coated tablets. </strong><strong>&nbsp;</strong></p><p>Severe skin reactions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may blister and looks like small targets (central dark spots, surrounded by paler area with a dark ring around the edge) (erythema multiforme)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe widespread rash with blisters and peeling skin, particularly occurrngng around the mouth &nbsp;Nose, eyes and genitals (Stevens - Johnson syndrome). &nbsp;If you notice any of these symptoms contact a doctor urgently.</p><p>&nbsp;</p><p>Most of the other side effects reported have been mild and have not lasted very long <strong>Very common: affects more than 1 user in 10</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick and being sick (nausea and vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&nbsp;</p><p>Common: affects 1 to 10 users in 100</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleeping problems (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strange dreams</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (pruritus)</p><p>&nbsp;</p><p><strong>common side effects, which may show up in your blood tests are: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced numbers of red blood cells (anaemia) which can cause tiredness, headaches and Shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced numbers of white blood cells (neutropenia) which make you more likely to catch infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of sodium in the blood (hyponatraemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in liver enzymes. &nbsp;</p><p>&nbsp;</p><p>Uncommon: affects 1 to 10 users in 1,000</p><p>These may affect up to 1 in 100 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an unusual awareness of abnormal beating of the heart (palpitations) swelling and redness of the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red swollen patches on the skin (hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss. &nbsp;</p><p>&nbsp;</p><p><strong>Uncommon side effects that may show up in your blood tests: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in amylase (an enzyme produced in the pancreas).</p><p>&nbsp;</p><p><strong>Rare: affects 7 to 10 users in 10,000 </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seeing or hearing things that are not there (hallucinations)</p><p>&nbsp;</p><p>Other side effects. &nbsp;Other side effects have occurred in a small number of people but their exact frequency is unknown. &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the liver (hepatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blockage of the bile ducts (cholestatis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in heart rate (tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the blood vessels (vasculitis) which may be visible as red orpurple raised spots on the skin but can affect other parts of the body &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (seizure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; panic attacks,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; crying nightmares</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe mental health problem in which the person loses contact with reality and is unable to think and judge clearly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blisters</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; peeling skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sensitivity of the skin to sunlight&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on your stomach (gastric intolerance).</p><p>&nbsp;</p><p>Other side effects that may show up in your blood tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adecrease in all types of blood cells (pancytopenia),</p><p>&nbsp;</p><p><strong>To report any side effects: </strong></p><p>If you get any side effects, talk to your doctor or pharmacist. &nbsp;Includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine</p><p>&nbsp;</p><p><strong>&nbsp;To report any side effect (s); Kindly Contact: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>The National Pharmacovigilance and Drug Safety Center (NPC) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: + 966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at + 966-11-2038222, Exts: 2317-2356-2340. &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E - mail:&nbsp;npc.drug@sfda.gov.sa&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg; C</p><p>Do not use this medicine after the expiry date, which is stated on the blister and the carton after EXP. The expiry date refers to the last day of that month.</p><p>Store in the original package in order to protect from moisture,</p><p>Do not &nbsp;throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are atovaquone and proguanil hydrochloride. &nbsp;Each film - coated tablet contains 250 mg atovaquone and 100 mg proguanil hydrochloride. &nbsp;The other ingredients are:</p><p><strong>&nbsp;</strong></p><p><strong>Core </strong></p><p>Poloxamer 188, Microcrystalline Cellulose, Low - substituted Hydroxypropyl Cellulose, Povidone K30, Sodium Starch Glycolate Type A, Silica Colloidal anhydrous, Magnesium Stearate</p><p><strong>Coating </strong></p><p>Hypromellose, Titanium Dioxide (E171), Iron Oxide Red (E171) &nbsp;400, Macrogol 8000</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Malaust 250 mg 100 mg Film - coated tablets are pinkish brown to brown colored, circular, biconvex beveled tablets edge Film - coated with '404  debossed on one side and 'G' debossed on the other side.  Atovaquone / Proguanil Hydrochloride 250 mg / 100 mg Film - coated are supplied in PVC / PVDC (clear) and hard tempered PVC / PVDC - Aluminum foil blister packs containing 12 tablets 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Glenmark Pharmaceuticals Limited Plot No. &nbsp;S - 7, Colvale Industrial Estate, Colvale, Bardez, Goa 403 513. INDIA</p><p><strong>Manufactured by: Glenmark Pharmaceuticals Limited </strong></p><p>At: Plot No. &nbsp;S - 7, Colvale Industrial Estate, Colvale. &nbsp;Bardez, Goa 403 513 INDIA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                February 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي دواء مالايست ۲5۰ مجم / 100 أقراص مغلفة إلى مجموعة من الأدوية تعرف باسم الأدوية المضادة للملاريا . حيث يتكون من مادتين فعالتين &quot; أتوفا كون وبروجوانيل هيدروكلوريد &quot; .</p><p dir="RTL">يستخدم دواء مالايست ۲5۰ مجم/100 مجم اقراص مغلفة في علاج الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للوقاية من الإصابة بمرض الملاريا في المرضى من البالغين والأطفال الذين يزيد أوزانهم عن 40 كجم .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج مرض الملاريا في المرضى البالغين والأطفال الذين يزيد أوزانهم عن ۱۱ كجم.</p><p dir="RTL">&nbsp;تنتشر الملاريا بسبب لدغة من البعوض المصاب بها ، حيث ينتقل طفيل الملاريا ( متصورة منجلية) إلى مجرى الدم. يعمل دواء مالايست ۲5۰ مجم/100 مجم اقراص مغلفة على منع الإصابة بالملاريا من خلال قتل الطفيل المسبب لها . كما يقوم دواء مالايست ۲5۰ مجم / ۱۰۰ مجم اقراص مغلفة أيضا بقتل وتدمير الطفيليات المسببة للملاريا في المرضى المصابين فعليا بمرض الملاريا .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;احم ( حافظ على) نفسك من الإصابة بالملاريا : </strong></p><p dir="RTL">يمكن الإصابة بالملاريا في أي فئة عمرية ، يعد مرض الملاريا خطيرا ولكن يمكن الوقاية منه.</p><p dir="RTL">اتباع التعليمات الخاصة ايضا يعتبر أمرا هاما من اجل تجنب التعرض للدغات البعوض ، بالإضافة إلى تناول دواء مالايست ۲5۰ مجم / ۱۰۰مجم أقراص مغلفة ، يمكنك القيام بما يلي :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام بخاخ طارد للحشرات على المناطق المكشوفة من الجلد .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتداء ملابس ملونة فاتحة ثغطي معظم أجزاء الجسم ، خاصة بعد غروب الشمس لأن هذا هو الوقت الذي يكون فيه البعوض اكثر نشاط .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوم في غرفة مغلقة النوافذ او تحت ناموسية ورش مبيدات الحشرات لمنع دخول البعوض .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغلاق النوافذ والأبواب عند غروب الشمس ، إذا لم يكن عليها شبكة معدنية ( شیش ) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام مبيد حشري ( سواء كان من أنواع اجهزة الإبادة او المبيدات الحشرية او اي مواد أساليب أخرى ) للتخلص من البعوض أو منعهم من دخول الغرفة .</p><p dir="RTL">يرجي التحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك ، إذا كنت بحاجة إلى المزيد من النصائح</p><p dir="RTL">لا يزال خطر الإصابة بالملاريا موجودا وقائما ، بالرغم من اتباع جميع التحذيرات الخاصة بذلك قد لا تظهر أعراض الإصابة بالملاريا إلا بعد عدة ايام او اسابيع او حتى شهور عقب العودة من السفر ، حيث يستغرق بعض أنواع عدوی الملاريا وقتا طويلا حتى ظهور الأعراض الخاصة بها . ينبغي استشارة الطبيب المعالج لك فورا، إذا عانيت من الأعراض التالية : ارتفاع درجة الحرارة او صداع رعشة أو شعور بتعب عقب العودة إلى المنزل .</p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحظر تناول دواء مالايست ۲5۰ مجم / ۱۰۰ مجم اقراص مغلفة في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه مادة أتوفاکون و/ أو بروجوانيل هيدروكلوريد أو تجاه أي مكون من المكونات الأخرى الداخلة في تركيب هذا الدواء ( المذكورة في القسم رقم 6 ) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كلوي حاد ، وتستخدم الدواء للوقاية من مرض الملاريا .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL"><strong>عند استخدامه للوقاية من الإصابة بالملاريا :</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي تناول جرعة أخرى من دواء ملايست 250مجم/100مجم أقراص مغلفة، اذا كنت مريضا واصبت بالقيء بعد مرور ساعة واحدة من تناول الأقراص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي تناول الجرعة الكاملة من دواء ملايست 250مجم/100مجم أقراص مغلفة حيث قد تحتاج إلى وصفة طبية أخرى من الطبيب المعالج لك إذا كان ينبغي تناول المزيد من الأقراص عند الإصابة بالقيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُعد استخدام وسائل حماية إضافية امرا هاما من اجل تجنب التعرض للدغات البعوض مثل المستحضرات الطاردة للحشرات وناموسيات السرير. إذا كنت لاتزال تعاني من القيء قد يقلل ذلك من فعالية دواء مالايست 250محم/100 مجم أقراص مغلفة نتيجة لنقص الكمية الممتصة من الدواء في الجسم. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج الإصابة بالملاريا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابلغ الطبيب المعالج لك ، إذا كنت تعاني من قيء وإسهال حيث ينبغي إجراء فحوصات الدم بانتظام إذا كنت لا تزال تعاني من القيء والاسهال فقد يقلل ذلك من فعالية دواء ملايست &nbsp;250مجم/100 مجم اقراص مغلفة نتيجة لنقص الكمية الممتصة من الدواء في الجسم. ستقيس فحوصات الدم نسبة التخلص من طفيل الملاريا من الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقوم الطبيب المعالج لك بوصف دواء اخر بدلا من دواء مالايست &nbsp;250 مجم/100 مجم اقاص مغلقة ، إذا كت تعاني من مرض حاد في الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقوم الطبيب المعالج لك بوصف دواء اخربدلا من دواء مالايست 250 مجم/ ۱۰۰ مجم أقراص مغلفة، &nbsp;اذا اصبت بأحد أنواع العدوى اثناء فترة تتناول دواء مالايست.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقوم الطبيب المعالج لك بوصف دواء اخر متزامنا مع استخدام دواء مالايست 250 مجم/100 مجم أقراص مغلفة، إذا حدثت إصابات متكررة بالملاريا بعد التعافي سابقا منهما او إذا تمت الإصابة بها من قبل بنوع معين من الطفيليات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>استخدام أدوية أخرى مع دواء مالایست </strong><strong>۲5۰</strong><strong> مجم/ </strong><strong>۱۰۰</strong><strong> مجم أقراص مقلفة: </strong></p><p dir="RTL">ابلغ الطبيب المعالج لك أو الصيدلي الخاص بك ، إذا كنت تتناول أو تناولت مؤخرا أو قد تتناول أي أدوية أخرى ، حيث يمكن أن تؤثر بعض الأدوية على الية عمل دواء مالايست ۲5۰ مجم / 100 مجم أقراص مغلفة ، أو قد يزيد أو يضعف دواء مالايست 250 &nbsp;مجم / ۱۰۰ مجم أقراص مغلفة من فعالية الأدوية الأخرى التي يتم استخدامها بالتزامن مع هذا الدواء . حيث تشمل هذه الأدوية ما يلي :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتوكلوبراميد ، دواء يستخدم لعلاج الغثيان والقيء .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات حيوية من مجموعة تتراسیکلین ، ريفامبيسين ، ريفابوتين .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفافيرينز او بعض مثبطات الأنزيم البروتيني شديدة النشاط المستخدم لعلاج فيروس نقص المناعة البشرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إندينافير دواء يستخدم لعلاج الايدز .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين وأدوية أخرى مضادة لتخثر الدم .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيتوبوسايد دواء يستخدم لعلاج السرطان .</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ الطبيب المعالج لك ، إذا كنت تتلقى أي من هذه الأدوية . فقد يقرر الطبيب المعالج لك أن استخدام دواء مالايست ۲5۰ مجم/ ۱۰۰ مجم أقراص مغلفة غير مناسب لك أو أنك بحاجة إلى إجراء المزيد من الفحوصات الإضافية أثناء تناول هذا الدواء .</p><p dir="RTL">إذا بدأت في استخدام أية أدوية أخرى بالتزامن مع تناول دواء مالايست ۲5۰ مجم / ۱۰۰ مجم اقراص مغلفة ، فيتعين عليك إخبار الطبيب المعالج لك بذلك .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول دواء مالايست مع الطعام والشراب : </strong></p><p dir="RTL">ينبغي تناول دواء مالايست ۲5۰ مجم / 1۰۰ جم أقراص مغلفة ، إن أمكن ذلك ، مع الطعام أو شرب أي مشروب يحتوي على اللبن . سيزيد تلك من نسبة الجرعة التي يمكن للجسم امتصاصها من دواء مالايست ۲5۰ مجم / ۱۰۰ مجم أقراص مغلفة ويجعل الدواء أكثر فعالية. يحظر طحن او سحق الأقراص .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية:</strong></p><p dir="RTL">يحظر تناول دواء مالايست ۲5۰ مجم / ۱۰۰ مجم أقراص مغلفة إذا كنت حاملا أو تخططين لإنجاب طفل ، مالم يوصي الطبيب المعالج لك بذلك . استشيري الطبيب المعالج لك أو الصيدلي الخاص بك للحصول على النصيحة قبل تناول دواء مالايست ۲5۰ مجم / ۱۰۰ مجم أقراص مغلفة. يحظر عليك ممارسة الرضاعة الطبيعية عند تناولك دواء مالايست ۲5۰ مجم/ 100مجم &nbsp;أقراص مغلفة لأنه يفرز في لبن الأم ويمكن أن يضر الطفل .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات:</strong></p><p dir="RTL">&nbsp;يحظر قيادة السيارات ، إذا كنت تشعر بالدوخة ، حيث قد يجعل دواء مالايست ۲5۰ مجم / 100 مجم أقراص مغلفة بعض المرضى يشعرون بالدوخة . فإذا حدث ذلك ، فلا تقود السيارات أو تشغل أي آلات أو تشترك في اي مهام قد تضر بك أو بمن حولك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء تماما كما اخبرك الطبيب المعالج لك أو الصيدلي الخاص بك استشر الطبيب المعالج لك أو الصيدلي الخاص بك إذا كنت غير متاكد من كيفية التناول .</p><p dir="RTL">ينبغي تناول دواء مالايست ۲5۰ مجم / 100 مجم أقراص مغلفة ، إن أمكن ذلك ، مع الطعام أو شرب أي مشروب يحتوي على اللبن . ينصح بتناول دواء مالايست ۲5۰ مجم / ۱۰۰ مجم في نفس الوقت يوميا .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يستخدم دواء مالايست للوقاية من الملاريا : </strong></p><p dir="RTL">الجرعة المعتادة للمرضى من البالغين والأطفال الذين تزيد أوزانهم عن 40 كجم هي قرص واحد يوميا ، يتم تناوله على النحو التالي:</p><p dir="RTL"><strong>بالنسبة للمرضى من الأطفال ، استشر الطبيب المعالج لك . </strong></p><p dir="RTL">لا ينصح باستخدام دواء مالايست ۲5۰ مجم / 100 مجم أقراص مغلفة للوقاية &nbsp;من الملاريا في الأطفال أو البالغين او المراهقين الذين تقل اوزانهم عن 40 كجم .</p><p dir="RTL">قد يتوفر نوع أخر مختلف من دواء مالايست ۲5۰ مجم / 100 مجم أقراص مغلفة في الدولة التي تعيش بها يستخدم للوقاية من الملاريا في الأطفال .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للوقاية من الملاريا في المرضى من البالغين : </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابدأ في تناول دواء مالايست ۲5۰ مجم / ۱۰۰ أقراص مغلفة قبل يوم أو يومين من السفر الى أي منطقة موبوءة بالملاريا .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استمر في تناوله يوميا طوال مدة إقامتك في هذه الدولة، كما ينبغي الاستمرار في تناوله لمدة 7 أيام و بعد العودة إلى منطقة خالية من الملاريا . ينبغي تناول جرعة علاجية كاملة من دواء مالايست ۲5۰ مجم / ۱۰۰ مجم أقراص مغلفة للحصول على أقصى حماية . إن إيقاف تناول دواء مالايست مبكرا ، يعرضك خطر الإصابة بالملاريا ، يحث تستغرق الدورة العلاجية الكاملة 7 أيام للتأكد من القضاء على أي طفيليات قد تكون في الدم بعد لدغة من البعوض المصاب .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام دواء مالايست لعلاج الملاريا : </strong></p><p dir="RTL">الجرعة المعتادة للمرضى من البالغين هي 4 أقراص مرة واحدة يوميا لمدة 3 أيام .</p><p dir="RTL">بالنسبة للمرضى من الأطفال الذين تتراوح أوزانهم من 11 كجم فاكثر ، تعتمد الجرعة على وزن الجسم:</p><p dir="RTL">&ge; ۱۱ إلى &lt; ۲۰ كجم : عدد ۱ : يوميا لمدة 3 أيام</p><p dir="RTL">&ge; ۲۱ إلى &lt; ۳۰ كجم : عدد ۲ يوميا لمدة 3 أيام</p><p dir="RTL">&nbsp;&ge;۳۱ إلى &lt; 40 كجم : عدد 3 يوميا لمدة 3 أيام .</p><p dir="RTL">أكثر من 40 كجم : نفس الجرعة الخاصة بالمرضى من البالغين .</p><p dir="RTL">لا ينصح باستخدام دواء مالايست ۲5۰ مجم / 100 مجم أقراص مغلفة لعلاج الملاريا في الأطفال الذين تقل اوزانهم عن 11 كجم.</p><p dir="RTL">&nbsp;يرجى التحدث إلى الطيب المعالج لك ، بالنسبة للأطفال الذين تقل أوزانهم عن 11 كجم . قد يتوفر نوع أخر مختلف من دواء مالايست ۲5۰ مجم / ۱۰۰ مجم أقراص مغلفة في الدولة التي تعيش فيها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من دواء مالايست </strong><strong>۲۰۰</strong><strong> مجم / 100 مجم أقراص مغلفة : </strong></p><p dir="RTL">اتصل بالطبيب المعالج لك أو الصيدلي الخاص بك للحصول على المشورة ، كما ينبغي اصطحاب عبوة دواء مالايست ۲5۰ مجم / ۱۰۰ مجم اقراص مغلفة معك لعرضها على الطبيب إذا كان ذلك ممكنا .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول دواء مالايست : </strong></p><p dir="RTL">يعتبر تناول الجرعة العلاجية الكاملة من دواء مالايست ۲5۰ مجم / 100 مجم أقراص مغلفة أمرا هاما .</p><p dir="RTL">إذا نسيت تناول إحدى الجرعات ، فلا تقلق ، ولكن تناول الجرعة المنسية بمجرد تذكرك لها. ثم استمر في تناول الدواء كالمعتاد . لا تتناول جرعة مضاعفة لتعويض جرعة نسيتها .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتوقف عن تناول أتوفاكون وبروجوانيل هيدروكلوريد دون نصيحة.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استمر في تناول أتوفاگون وبروجوانيل هيدروكلوريد لمدة 7 أيام بعد عودتك إلى منطقة خالية من الملاريا .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي تناول جرعة علاجية كاملة من أتوفاكون وبروجوانيل هيدروكلوريد للحصول على أقصى حماية . إن إيقاف تناول دواء مالايست مبكرا ، يعرضك لخطر الإصابة بالملاريا ، يحث تستغرق الدورة العلاجية الكاملة 7 أيام للتأكد من قتل والقضاء على اي طفيليات قد تكون في الدم بعد لدغة من البعوض المصاب .</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجي التحدث إلى الطبيب المعالج لك او الصيدلي الخاص بك ، إذا كنت بحاجة إلى المزيد من النصائح إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، استشر الطبيب المعالج لك أو الصيدلي الخاص بك .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا الدواء ، مثله مثل كافة الأدوية الأخرى ، آثارا جانبية ، على الرغم من عدم حدوثها لجميع المرضى ، انتبه للأثار <strong>الجانبية التالية الخطيرة ، حيث عانى قليل من المرضى منها ولكن معدل تكرارها غير معروف</strong> .</p><p dir="RTL">تفاعلات الحساسية الخطيرة ، تشمل الأعراض التالية: &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي وحكة ؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازيز مفاجئ بالصدر ، ضيق بالصدر او الحلق أو صعوبة بالتنفس .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفون والوجه والشفتين واللسان أو أي أجزاء أخرى من الجسم</p><p dir="RTL"><strong>اتصل بالطبيب المعالج لك فورا ، إذا كنت تعاني من هذه الأعراض . وينبغي إيقاف تناول دواء مالايست </strong><strong>۲5۰</strong><strong> مجم / </strong><strong>۱۰۰</strong><strong> مجم اقراص مغلفة. </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تفاعلات جلدية خطيرة : </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي قد يكون مصحوبا بتكون بثور تبدو كبقع جلدية صغيرة ( بقع متوسطة داكنة محاطة بجزء من الجلد شاحب اللون مع وجود حلقات داكنة حول الحواف &ndash; ( خمامی متعدد الأشكال ) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واسع الانتشار مع ظهور بثور وتقشير الجلد ، وخاصة حول منطقة الفم والأنف والعينين والأعضاء التناسلية ( متلازمة ستيفنز جونسون ) . إذا لاحظت أيا من هذه الأعراض ، اتصل بالطبيب المعالج لك فورا.</p><p dir="RTL">معظم الآثار الجانبية الأخرى التي تم الإبلاغ عنها كانت بسيطة ولم تستمر طويلا .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثار جانبية شائعة جدا ( قد تؤثر على أكثر من مريض واحد من بين كل </strong><strong>۱۰</strong><strong> مرضی ) : </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بغثيان وتعب ( غثيان وقيء ) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأم بالمعدة .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة ( قد تؤثر على مريض واحد من بين كل </strong><strong>۱۰۰</strong><strong> مريض ) : </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات اثناء النوم ( أرق ) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحلام غربية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة قد تظهر في نتائج فحوصات الدم</strong><strong> :</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء ( فقر الدم التي يمكن وصداع وضيق التنفس .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء ( قلة خلايا العدلات ) مما قد يجعلك أكثر عرضة للإصابة بالعدوی &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في الدم ( نقص صوديوم الدم ) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدلات إنزيمات الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة ( قد تؤثر على عدد يتراوح من 1 إلى 10 من المرضى من بين كل </strong><strong>۱۰۰۰</strong><strong> مريض ) :</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور غير عادي بضربات قلبية غير طبيعية ( خفقان ) ، تورم واحمرار الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء متورمة على الجلد ( شری ) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة قد تظهر في نتائج فحوصات الدم : </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستوي انزيم الأميليز ( إنزيم ينتج من البنكرياس ) .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة ( قد تؤثر على عدد يتراوح من مريض واحد إلى 10 مرضى من بين كل </strong><strong>۱۰۰۰۰</strong><strong> مريض ) </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو سماع أشياء غير موجودة ( هلوسة ) .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية اخري : حيث عاني قليل من المرضى منها ولكن معدل تكرارها غير معروف </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد ( التهاب كبدي )</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد القنوات الصفراوية ( رکود صفراوي )</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في معدل ضربات القلب ( سرعة ضربات القلب )</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية الذي يظهر مثل بقع حمراء أو أرجوانية مرفوعة عن الجلد ولكن يمكن أن تؤثر على اجزاء اخرى من الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات تشنجية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات هلع وبكاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوابيس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات شديدة بالحالة العقلية حيث يفقد فيها الشخص الاتصال بالواقع ولا يستطيع التفكير ورؤية الأمور بوضوح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح بالفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقشر الجلد .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية الجلد لأشعة الشمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاثيرات على المعدة ( تهيج المعدة ) .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية اخرى تظهر في نتائج فحوصات الدم </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد جميع انواع خلايا الدم (قلة الكريات الشاملة )</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية </strong></p><p dir="RTL">إذا كنت تعاني من أية آثار جانبية ، فتحدث إلى الطبيب المعالج لك او الصيدلي الخاص بك . يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذا التشرة عن طريق الإبلاغ عن الآثار الجانبية ، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;&nbsp;للإبلاغ عن أي آثار جانبية: </strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ والسلامة الدوائية </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفاكس: 7662 &ndash; 205 &ndash; 11 &ndash; 966 + &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على : 8222 &ndash; 203 &ndash; 11 - &nbsp;966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحويلات داخلية : 2317 &ndash; 2356 &ndash; 2340&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رقم مركز اتصالات الهيئة العامة للغذاء والدواء : ۱۹۹9۹</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني &nbsp;www.sfda.gov.sa/npc</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول مجلس التعاون الخليجي الأخرى: يرجى الاتصال بالسلطة المختصة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء بعيدا عن متناول ورؤية الأطفال .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء في درجة حرارة أقل من ۳۰ درجة مئوية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدوا بعد انتهاء الصلاحية المدون على الشريط والعبوة بعد كلمة &quot; EXP &quot; حيث يشير تاريخ انتهاء الصلاحية إلى أخر الشهر ويحفظ الدواء داخل العبوة الأصلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من اي &nbsp;دواء في الصرف الصحي او مع النفايات المنزلية استشر الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها . تساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;<strong>أ . على ماذا يحتوي دواء مالايست ؟ </strong></p><p dir="RTL"><strong>المواد الفعالة هي</strong> اتوفاكون وبروجوانيل هيدروكلوريد . يحتوي كل قرص مغلف على 250 مجم اتوفاكون و ۱۰۰ مجم من بروجوانيل هيدروكلوريد .</p><p dir="RTL"><strong>المكونات الأخرى هي : </strong></p><p dir="RTL"><strong>مكونات المحتوى الداخلي للقرص : </strong></p><p dir="RTL">بوليكسامير ۱۸۸ ، سليلوز مبلور ، هيدروكسي بروبيل سليلوز منخفض، بوفيدون كيه 30 ، جليكولات صوديوم النشا من النوع أ ، سيليكون غروي لاماني ، ستيرات المغنيسيوم.</p><p dir="RTL">&nbsp;<strong>مكونات المحتوى الخارجي للقرص : </strong></p><p dir="RTL">هيبرومیللوز ، ثاني اكسيد التيتانيوم ( E ) 171 ، أكسيد الحديد الأحمر ( E ) 172 ، ماکروجول 4۰۰ ، ماکروجول ۸۰۰۰ .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>دواء مالايست </strong><strong>۲5۰</strong><strong> مجم / </strong><strong>۱۰۰</strong><strong> مجم اقراص</strong> مغلفة عبارة عن اقراص مغلفة يتراوح لونها من اللون البني إلى البني الوردي ، دائرية الشكل ، محدبة الوجهين ، ذات حواف ماتلة محفور على احد جانبيها حرف &quot;G&quot; وعلى الجانب الاخر رقم 404.</p><p dir="RTL"><strong>يتم تعبئة دواء مالايست </strong><strong>۲5۰</strong><strong> مجم / </strong><strong>۱۰۰</strong><strong> مجم أقراص مغلفة</strong> في شرائط كل شريط مصنوع من مادة الالمنيوم كلوريد متعدد الفاينيل،ثناني كلوريد الفينيليدين ( نقي ) وبكل شريط ۱۲ فرص في علبة كرتون .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ج . الشركة صاحبة حق التسويق</strong></p><p dir="RTL">&nbsp;شركة جلينمارك للأدوية المحدودة قطعة رقم ۷ - S ، المنطقة الصناعية بكولفال ،</p><p dir="RTL">باردیز ، کرا 403513 ، الهند</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">شركة جلينمارك للأدوية المحدودة قطعة رقم ۷ - S ، المنطقة الصناعية بكولفال ،</p><p dir="RTL">باردیز ، کرا 403513 ، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2018 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Atovaquone and Proguanil Hydrochloride Tablets 250mg / 100mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains
Atovaquone Ph.Eur.……………………250 mg
Proguanil hydrochloride Ph.Eur.……….100 mg
“For a full list of excipients, see section 6.1.”
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
Pinkish brown to brown colored, circular, biconvex beveled edged film coated tablets with
‘404’ debossed on one side and ‘G’ debossed on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet is a fixed dose combination of<br />atovaquone and proguanil hydrochloride which acts as a blood schizonticide and also has<br />activity against hepatic schizonts of Plasmodium falciparum. It is indicated for:<br />Prophylaxis of Plasmodium falciparum malaria.<br />Treatment of acute, uncomplicated Plasmodium falciparum malaria.<br />Because Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet is effective against drug<br />sensitive and drug resistant P. falciparum it is especially recommended for prophylaxis and<br />treatment of P. falciparum malaria where the pathogen may be resistant to other antimalarials.<br />Official guidelines and local information on the prevalence of resistance to antimalarial drugs<br />should be taken into consideration. Official guidelines will normally include WHO and<br />public health authorities&#39; guidelines&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Method of administration<br />The daily dose should be taken with food or a milky drink (to ensure maximum absorption) at<br />the same time each day.<br />If patients are unable to tolerate food, fixed dose combination should be administered, but<br />systemic exposure of atovaquone will be reduced. In the event of vomiting within 1 hour of<br />dosing a repeat dose should be taken.<br />Posology<br />Prophylaxis:<br />Prophylaxis should</p><p>commence 24 or 48 hours prior to entering a malaria-endemic area,<br />&bull; continue during the period of the stay<br />&bull; continue for 7 days after leaving the area.<br />In residents (semi-immune subjects) of endemic areas, the safety and effectiveness of<br />Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet has been established in studies of<br />up to 12 weeks.<br />In non-immune subjects, the average duration of exposure in clinical studies was 27 days.<br />Dosage in Adults<br />One Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet daily.<br />Atovaquone 250mg/Proguanil hydrochloride 100mg Tablets are not recommended for<br />malaria prophylaxis in persons under 40 kg bodyweight.<br />Treatment<br />Dosage in Adults<br />Four Atovaquone 250mg/Proguanil hydrochloride 100mg Tablets as a single dose for three<br />consecutive days.<br />Dosage in Children<br />11-20 kg bodyweight. One tablet daily for three consecutive days.<br />21-30 kg bodyweight. Two tablets as a single dose for three consecutive days.<br />31-40 kg bodyweight. Three tablets as a single dose for three consecutive days.<br />&gt;40 kg bodyweight. Dose as for adults.<br />Dosage in the Elderly<br />A pharmacokinetic study indicates that no dosage adjustments are needed in the elderly.<br />Dosage in Hepatic Impairment<br />A pharmacokinetic study indicates that no dosage adjustments are needed in patients with<br />mild to moderate hepatic impairment. Although no studies have been conducted in patients<br />with severe hepatic impairment, no special precautions or dosage adjustment are anticipated<br />Dosage in Renal Impairment<br />Pharmacokinetic studies indicate that no dosage adjustments are needed in patients with mild<br />to moderate renal impairment. In patients with severe renal impairment (creatine clearance<br />&lt;30 mL/min) alternatives to Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet for<br />treatment of acute P. falciparum malaria should be recommended whenever possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
It is contraindicated for prophylaxis of P. falciparum malaria in patients with severe renal
impairment (creatinine clearance <30 mL/min).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Persons taking Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet for prophylaxis or<br />treatment of malaria should take a repeat dose if they vomit within 1 hour of dosing. In the<br />event of diarrhoea, normal dosing should be continued. Absorption of atovaquone may be<br />reduced in patients with diarrhoea or vomiting, but diarrhoea or vomiting was not associated<br />with reduced efficacy in clinical trials of Atovaquone 250mg/Proguanil hydrochloride 100mg<br />Tablet for malaria prophylaxis. However, as with other antimalarial agents, subjects with<br />diarrhoea or vomiting should be advised to continue with malaria prevention measures by<br />complying with personal protection measures (repellants, bednets).<br />In patients with acute malaria who present with diarrhoea or vomiting, alternative therapy<br />should be considered. If Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet is used<br />to treat malaria in these patients, parasitaemia and the patient&#39;s clinical condition should be<br />closely monitored.</p><p>Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet has not been evaluated for the<br />treatment of cerebral malaria or other severe manifestations of complicated malaria including<br />hyperparasitaemia, pulmonary oedema or renal failure.<br />Occasionally, severe allergic reactions (including anaphylaxis) have been reported in patients<br />taking Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet. If patients experience an<br />allergic reaction Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet should be<br />discontinued promptly and appropriate treatment initiated.<br />Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet has been shown to have no<br />efficacy against hypnozoites of Plasmodium vivax as parasite relapse occurred commonly<br />when P. vivax malaria was treated with Atovaquone 250mg/Proguanil hydrochloride 100mg<br />Tablets alone. Travellers with intense exposure to P. vivax or P. ovale, and those who<br />develop malaria caused by either of these parasites, will require additional treatment with a<br />drug that is active against hypnozoites.</p><p>In the event of recrudescent infections due to P. falciparum after treatment with Atovaquone<br />250mg/Proguanil hydrochloride 100mg Tablet, or failure of chemoprophylaxis with<br />Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet, patients should be treated with a<br />different blood schizonticide as such events can reflect a resistance of the parasite.<br />Parasitaemia should be closely monitored in patients receiving concurrent tetracycline.<br />The concomitant administration of Atovaquone 250mg/Proguanil hydrochloride 100mg<br />Tablet and efavirenz or boosted protease-inhibitors should be avoided whenever possible.<br />The concomitant administration of atovaquone and proguanil hydrochloride tablet and<br />rifampicin or rifabutin is not recommended.<br />Concurrent use of metoclopramide is not recommended. Another antiemetic treatment should<br />be given.</p><p>Caution is advised when initiating or withdrawing malaria prophylaxis or treatment with<br />atovaquone and proguanil hydrochloride tablet in patients on continuous treatment with<br />warfarin and other coumarin based anticoagulants.<br />Atovaquone can increase the levels of etoposide and its metabolite.<br />In patients with severe renal impairment (creatinine clearance &lt;30 mL/min) alternatives to<br />atovaquone and proguanil hydrochloride tablet for treatment of acute P. falciparum malaria<br />should be recommended whenever possible.<br />The safety and effectiveness of atovaquone 250mg/proguanil hydrochloride 100mg tablets<br />has not been established for prophylaxis of malaria in patients who weigh less than 40kg, or<br />in the treatment of malaria in paediatric patients who weigh less than 11kg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of rifampicin or rifabutin is not recommended as it is known to<br />reduce plasma concentrations of atovaquone levels by approximately 50% and 34%,<br />respectively.<br />Concomitant treatment with metoclopramide has been associated with a significant decrease<br />(about 50 %) in plasma concentrations of atovaquone. Another antiemetic treatment should<br />be given.<br />When given with efavirenz or boosted protease-inhibitors, atovaquone concentrations have<br />been observed to decrease as much as 75%. This combination should be avoided whenever<br />possible.</p><p>Proguanil may potentiate the effect of warfarin and other coumarin based anticoagulants<br />which may lead to an increase in the risk of haemorrhage. The mechanism of this potential<br />drug interaction has not been established. Caution is advised when initiating or withdrawing<br />malaria prophylaxis or treatment with atovaquone-proguanil in patients on continuous<br />treatment with oral anticoagulants. The dose of the oral anticoagulant may need to be<br />adjusted during Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet treatment or after<br />its withdrawal, based on INR results.<br />Concomitant treatment with tetracycline has been associated with decreases in plasma<br />concentrations of atovaquone.<br />The co-administration of atovaquone at doses of 45mg/kg/day in children (n=9) with acute<br />lymphoblastic leukaemia for prophylaxis of PCP was found to increase the plasma<br />concentrations (AUC) of etoposide and its metabolite etoposide catechol by a median of 8.6%<br />(P=0.055) and 28.4% (P=0.031) (respectively compared to the co-administration of etoposide<br />and sulfamethoxazole-trimethoprim). Caution should be advised in patients receiving<br />concomitant therapy with etoposide.</p><p>Proguanil is primarily metabolised by CYP2C19. However, potential pharmacokinetic<br />interactions with other substrates, inhibitors (e.g. moclobemide, fluvoxamine) or inducers<br />(e.g. artemisinin, carbamazepine) of CYP2C19 are unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of atovaquone and proguanil hydrochloride when administered concurrently for<br />use in human pregnancy has not been established and the potential risk is unknown.<br />Animal studies showed no evidence for teratogenicity of the combination. The individual<br />components have shown no effects on parturition or pre- and post-natal development.<br />Maternal toxicity was seen in pregnant rabbits during a teratogenicity study.<br />The use of Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet in pregnancy should<br />only be considered if the expected benefit to the mother outweighs any potential risk to the<br />foetus.</p><p>The proguanil component of combination of atovaquone and proguanil hydrochloride tablet<br />acts by inhibiting parasitic dihydrofolate reductase. There are no clinical data indicating that<br />folate supplementation diminishes drug efficacy. For women of childbearing age receiving<br />folate supplements to prevent neural tube birth defects, such supplements should be<br />continued while taking fixed dose combination of atovaquone and proguanil hydrochloride<br />tablet.<br />Breast-feeding<br />The atovaquone concentrations in milk, in a rat study, were 30% of the concurrent<br />atovaquone concentrations in maternal plasma. It is not known whether atovaquone is<br />excreted in human milk.<br />Proguanil is excreted in human milk in small quantities.<br />Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet should not be taken by breastfeeding<br />women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dizziness has been reported. Patients should be warned that if affected they should not drive,<br />operate machinery or take part in activities where this may put themselves or others at risk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials of Atovaquone 250mg/Proguanil hydrochloride 100mg Tablets in the<br />treatment of malaria the most commonly reported adverse reactions were abdominal pain,<br />headache, anorexia, nausea, vomiting, diarrhoea and coughing. In clinical trials of<br />Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet for prophylaxis of malaria, the<br />most commonly reported adverse reactions were headache, abdominal pain and diarrhoea.<br />The following table provides a summary of adverse reactions that have been reported to have<br />a suspected (at least possible) causal relationship to treatment with atovaquone-proguanil in<br />clinical trials and spontaneous post-marketing reports. The following convention is used for<br />the classification of frequency: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10);</p><p>uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); not known (cannot be<br />estimated from the available data).<br />There are limited long term safety data in children. In particular, the long-term effects of<br />Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet on growth, puberty and general<br />development have not been studied.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is insufficient experience to predict the consequences or suggest specific management<br />of Atovaquone 250mg/Proguanil hydrochloride 100mg Tablet overdose. However, in the<br />reported cases of atovaquone overdose, the observed effects were consistent with known<br />undesirable effects of the drug. If overdose occurs, the patient should be monitored and<br />standard supportive treatment applied.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimalarials, ATC Code: P01B B51<br />Mode of Action<br />The constituents of combination tablet of Atovaquone 250mg/Proguanil hydrochloride<br />100mg, atovaquone and proguanil hydrochloride, interfere with two different pathways<br />involved in the biosynthesis of pyrimidines required for nucleic acid replication. The<br />mechanism of action of atovaquone against P. falciparum is via inhibition of mitochondrial<br />electron transport, at the level of the cytochrome bc1 complex, and collapse of mitochondrial<br />membrane potential. One mechanism of action of proguanil, via its metabolite cycloguanil, is<br />inhibition of dihydrofolate reductase, which disrupts deoxythymidylate synthesis. Proguanil<br />also has antimalarial activity independent of its metabolism to cycloguanil, and proguanil, but<br />not cycloguanil, is able to potentiate the ability of atovaquone to collapse mitochondrial<br />membrane potential in malaria parasites. This latter mechanism may explain the synergy seen<br />when atovaquone and proguanil are used in combination.</p><p>Microbiology<br />Atovaquone has potent activity against Plasmodium spp (in vitro IC50 against P. falciparum<br />0.23-1.43 ng/mL).<br />Atovaquone is not cross-resistant with any other antimalarial drugs in current use. Among<br />more than 30 P. falciparum isolates, in vitro resistance was detected against chloroquine<br />(41% of isolates), quinine (32% of isolates), mefloquine (29% of isolates), and halofantrine<br />(48% of isolates) but not atovaquone (0% of isolates).<br />The antimalarial activity of proguanil is exerted via the primary metabolite cycloguanil (in<br />vitro IC50 against various P. falciparum strains of 4-20 ng/mL; some activity of proguanil and<br />another metabolite, 4-chlorophenylbiguanide, is seen in vitro at 600-3000 ng/mL).<br />In in vitro studies of P. falciparum the combination of atovaquone and proguanil was shown<br />to be synergistic. This enhanced efficacy was also demonstrated in clinical studies in both<br />immune and non-immune patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no pharmacokinetic interactions between atovaquone and proguanil at the<br />recommended dose. In clinical trials, where children have received Atovaquone<br />250mg/Proguanil hydrochloride Tablet dosed by bodyweight, trough levels of atovaquone,<br />proguanil and cycloguanil in children are generally within the range observed in adults.<br />Absorption<br />Atovaquone is a highly lipophilic compound with low aqueous solubility. In HIV-infected<br />patients, the absolute bioavailability of a 750 mg single dose of atovaquone tablets taken with<br />food is 23% with an inter-subject variability of about 45%.<br />Dietary fat taken with atovaquone increases the rate and extent of absorption, increasing<br />AUC 2-3 times and Cmax 5 times over fasting. Patients are recommended to take<br />Atovaquone 250mg/Proguanil hydrochloride tablets with food or a milky drink.<br />Proguanil hydrochloride is rapidly and extensively absorbed regardless of food intake.<br />Distribution<br />Apparent volume of distribution of atovaquone and proguanil is a function of bodyweight.</p><p>Atovaquone is highly protein bound (&gt;99%) but does not displace other highly protein bound<br />drugs in vitro, indicating significant drug interactions arising from displacement are unlikely.<br />Following oral administration, the volume of distribution of atovaquone in adults and<br />children is approximately 8.8 L/kg.<br />Proguanil is 75% protein bound. Following oral administration, the volume of distribution of<br />proguanil in adults and children ranged from 20 to 42 L/kg.</p><p>In human plasma the binding of atovaquone and proguanil was unaffected by the presence of<br />the other.<br />Biotransformation<br />There is no evidence that atovaquone is metabolized and there is negligible excretion of<br />atovaquone in urine with the parent drug being predominantly (&gt;90%) eliminated unchanged<br />in faeces.<br />Proguanil hydrochloride is partially metabolized, primarily by the polymorphic cytochrome<br />P450 isoenzyme 2C19, with less than 40% being excreted unchanged in the urine. Its<br />metabolites, cycloguanil and 4-chlorophenylbiguanide, are also excreted in the urine.<br />During administration of combination at recommended doses proguanil metabolism status<br />appears to have no implications for treatment or prophylaxis of malaria.<br />Elimination<br />The elimination half-life of atovaquone is about 2-3 days in adults and 1-2 days in children.<br />The elimination half-lives of proguanil and cycloguanil are about 12-15 hours in both adults<br />and children.<br />Oral clearance for atovaquone and proguanil increases with increased bodyweight and is<br />about 70% higher in an 80 kg subject relative to a 40 kg subject. The mean oral clearance in<br />paediatric and adult patients weighing 10 to 80 kg ranged from 0.8 to 10.8 L/h for atovaquone<br />and from 15 to 106 L/h for proguanil.<br />Pharmacokinetics in the elderly<br />There is no clinically significant change in the average rate or extent of absorption of<br />atovaquone or proguanil between elderly and young patients. Systemic availability of<br />cycloguanil is higher in the elderly compared to the young patients (AUC is increased by<br />140% and Cmax is increased by 80%), but there is no clinically significant change in its<br />elimination half-life.<br />Pharmacokinetics in renal impairment<br />In patients with mild to moderate renal impairment, oral clearance and/or AUC data for<br />atovaquone, proguanil and cycloguanil are within the range of values observed in patients<br />with normal renal function.<br />Atovaquone Cmax and AUC are reduced by 64% and 54%, respectively, in patients with<br />severe renal impairment.<br />In patients with severe renal impairment, the elimination half- lives for proguanil (t&frac12; 39 h)<br />and cycloguanil (t&frac12; 37 h) are prolonged, resulting in the potential for drug accumulation with<br />repeated dosing.<br />Atovaquone and Proguanil Hydrochloride Tablets 250mg/100mg<br />Confidential<br />Pharmacokinetics in hepatic impairment<br />In patients with mild to moderate hepatic impairment there is no clinically significant change<br />in exposure to atovaquone when compared to healthy patients.<br />In patients with mild to moderate hepatic impairment there is an 85% increase in proguanil<br />AUC with no change in elimination half- life and there is a 65-68% decrease in Cmax and<br />AUC for cycloguanil.<br />No data are available in patients with severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeat dose toxicity:<br />Findings in repeat dose toxicity studies with atovaquone-proguanil hydrochloride<br />combination were entirely proguanil related and were observed at doses providing no<br />significant margin of exposure in comparison with the expected clinical exposure. As<br />proguanil has been used extensively and safely in the treatment and prophylaxis of malaria at<br />doses similar to those used in the combination, these findings are considered of little<br />relevance to the clinical situation.<br />Reproductive toxicity studies:<br />In rats and rabbits there was no evidence of teratogenicity for the combination. No data are<br />available regarding the effects of the combination on fertility or pre- and post-natal<br />development, but studies on the individual components of Atovaquone 250mg/Proguanil<br />hydrochloride Tablet have shown no effects on these parameters. In a rabbit teratogenicity<br />study using the combination, unexplained maternal toxicity was found at a systemic exposure<br />similar to that observed in humans following clinical use.<br />Mutagenicity:<br />A wide range of mutagenicity tests have shown no evidence that atovaquone or proguanil<br />have mutagenic activity as single agents.<br />Mutagenicity studies have not been performed with atovaquone in combination with<br />proguanil.<br />Cycloguanil, the active metabolite of proguanil, was also negative in the Ames test, but was<br />positive in the Mouse Lymphoma assay and the Mouse Micronucleus assay. These positive<br />effects with cycloguanil (a dihydrofolate antagonist) were significantly reduced or abolished<br />with folinic acid supplementation.<br />Carcinogenicity:<br />Oncogenicity studies of atovaquone alone in mice showed an increased incidence of<br />hepatocellular adenomas and carcinomas. No such findings were observed in rats and<br />mutagenicity tests were negative. These findings appear to be due to the inherent<br />susceptibility of mice to atovaquone and are considered of no relevance in the clinical<br />situation.</p><p>Oncogenicity studies on proguanil alone showed no evidence of carcinogenicity in rats and<br />mice.<br />Oncogenicity studies on proguanil in combination with atovaquone have not been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients<br />Microcrystalline Cellulose<br />Low substituted hydroxypropyl cellulose<br />Sodium Starch Glycolate<br />Poloxamer 188<br />Povidone K-30<br />Purified Water<br />Colloidal Silicon Dioxide<br />Magnesium Stearate<br />Opadry Brown 03C86943</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicabl</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An Alu-PVC/PVDC blister of 12 tablets packed in a carton alongwith leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Registered office:
Glenmark Pharmaceuticals Limited,
B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai road, Mumbai – 400 026, INDIA
Address for correspondence:
Glenmark House,
HDO-Corporate Building, Wing – A, B, D. Sawant Marg, Chakala, Off. Western express
highway, Andheri (East), Mumbai – 400 099, INDIA
Manufacturing site:
Glenmark Pharmaceuticals Ltd.
At: Plot No. S-7, Colvale Industrial Estate, Colvale, Bardez – Goa, 403513.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>